Neuroprotective effects of bilobalide are accompanied by a reduction of ischemia-induced glutamate release in vivo.
Neuroprotective properties of bilobalide, a specific constituent of Ginkgo extracts, were tested in a mouse model of stroke. After 24h of middle cerebral artery occlusion (MCAO), bilobalide reduced infarct areas in the core region (striatum) by 40-50% when given at 10mg/kg 1h prior to MCAO. Neuroprotection was also observed at lower doses, or when the drug was given 1h past stroke induction. Sensorimotor function in mice was improved by bilobalide as shown by corner and chimney tests. When brain metabolism in situ was monitored by microdialysis, MCAO caused a rapid disappearance of extracellular glucose in the striatum which returned to baseline levels after reperfusion. Extracellular levels of glutamate were increased by more than ten-fold in striatal tissue, and by four- to fivefold in hippocampal tissue (penumbra). Bilobalide did not affect glucose levels but strongly attenuated glutamate release in both core and penumbra regions. Bilobalide was equally active when given locally via the microdialysis probe and also reduced ischemia-induced glutamate release in vitro in brain slices. We conclude that bilobalide is a strong neuroprotectant in vivo at doses that can be used therapeutically in humans. The mechanism of action evidently involves reduction of glutamate release, thereby reducing excitotoxicity.
Department of Pharmacology, College of Pharmacy, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.
Dorothee
D
Lang
Cornelia
C
Kiewert
Alexander
A
Mdzinarishvili
Tina Maria
TM
Schwarzkopf
Rachita
R
Sumbria
Joachim
J
Hartmann
Jochen
J
Klein
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002545:Brain Ischemia / Q000378:metabolism* / Q000517:prevention & control*; D003517:Cyclopentanes / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005663:Furans / Q000494:pharmacology / Q000627:therapeutic use*; D046934:Ginkgolides / Q000494:pharmacology / Q000627:therapeutic use*; D018698:Glutamic Acid / Q000378:metabolism*; D051379:Mice; D017551:Microdialysis / Q000379:methods; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*
D003517:Cyclopentanes; D005663:Furans; D046934:Ginkgolides; D018696:Neuroprotective Agents; D018698:Glutamic Acid; C073710:bilobalide